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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary objective
To evaluate the impact of space spraying on malaria transmission and vector populations, or the incremental impact when applied in
combination with other malaria control methods, in comparison to equivalent conditions with no space spraying intervention.
Secondary objective
To guide future evaluations of strategies for which there is currently insufficient evidence to reliably assess the impact on malaria
transmission, by identifying the following.
• The range of space spraying strategies that have been trialled.
• Potentially promising strategies that have been used and warrant further evaluation.
• Strategies that have been used and appear unlikely to warrant further evaluation (for example, because they were found to be
infeasible or unacceptable).
B A C K G R O U N D
Description of the condition
WIth one child dying from malaria every two minutes, malaria
remains the world’s most serious vector-borne disease. In 2015,
an estimated 212 million new cases arose globally and the disease
caused 429,000 deaths, including 303,000 children under the age
of five (WHO 2016a). Most of the malaria burden falls on people
living in sub-Saharan Africa, where 90% of the total incidence
and 92% of all deaths occur (WHO 2016a). Malaria is also a
leading cause of global morbidity and was responsible for between
63 and 110 million disability-adjusted life years (DALYs) in 2010
(Murray 2012).
ThePlasmodium parasite species that causemalaria are transmitted
by the bite of a female Anopheles mosquito, and malaria preven-
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tion methods are predominantly geared towards reducing human
contact with infective mosquitoes. Insecticide-treated nets (ITNs)
and indoor residual spraying (IRS) prevent malaria transmission
in a variety of settings, and these methods have formed a central
component of the global strategy for malaria control (Lengeler
2004; Pluess 2010; WHO 2015). Between 2010 and 2015 the
estimated percentage of the at-risk population sleeping under an
ITN rose from 30% to 53%. This drive has coincided with a re-
duction in disease incidence of 21%, while malaria-related deaths
have fallen by 29% (WHO 2016a). However, these successes have
not been universal. Of the 91 countries with active transmission
of malaria, only 40 are on course to achieve the Global Technical
Strategy’s target of a 40% incidence reduction by 2020 (WHO
2015; WHO 2016a).
Description of the intervention
Space spraying refers to the process of dispersing liquid droplets
of insecticide into an area as a fog, with the aim of knocking
down and killing adult insects (Figure 1). For the purposes of this
Cochrane Review, the term implies distribution of insecticide on
a population level, rather than household use.
Figure 1. Space spraying with handheld equipment to control the mosquito population in Thailand
There are two different mechanisms for generating the fog for
space spraying. Thermal fogs use hot gas to vaporize a solution of
insecticide in a typically oil-based carrier liquid. Upon spraying,
the vapour interacts with colder air and forms a dense fog. In con-
trast, cold fogs are formed without the use of external heat, passing
the insecticide mixture instead through a mechanical apparatus
such as a high pressure nozzle or high-speed air flow. Cold fogging
commonly uses ultra-low-volume (ULV) preparations of insecti-
cide. The insecticide may also be delivered in three different ways;
using equipment that is either hand-held, vehicle-mounted, or ap-
plied from an aircraft (WHO 2003). Table 1 details the insecti-
cides and doses currently recommended by the World Health Or-
ganization (WHO) for space spraying use to control mosquitoes
(WHO 2016b).
Space spraying is regularly used in other public health and pest
control programmes. The intervention is an often-used strategy
for controlling outbreaks of dengue fever, a mosquito-borne viral
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disease with endemic regions that overlap extensively with those of
malaria (Esu 2010; Epelboin 2012). Both ground and aerial spray-
ing of insecticides have been regularly employed for the control
of tsetse flies and for other pests of public health or agricultural
importance (WHO 2003; Adam 2013).
Both thermal and cold fog applications are only effective while
the droplets remain airborne (WHO 2003). This length of time
is mainly dependent on the size of droplets distributed; a 10 µm
droplet spray will fall by 10 m in one hour, while 100 µm droplets
will fall the same distance in 36 seconds. Anopheles mosquitoes
typically bite in the evening, at night and in the earlymorning, and
it is recommended that the timing of spraying coincides with this
period of peak activity (WHO 2003; Pates 2005). Space spraying is
sometimes conducted during the day. In these cases, the intention
is to reach and kill mosquitoes in their resting locations, or induce
them to take flight through the fog (Najera 2003). Space spraying
targets only the current adultmosquito population. The technique
has little or no residual activity, and as juvenile stages are not
vulnerable to space spraying, multiple applications are required to
prevent the adult population being replaced (Najera 2003; Bonds
2012).
How the intervention might work
George Macdonald’s theory of vectorial capacity can be used to
explain the impact of malaria vector control interventions. Vecto-
rial capacity is a theoretical estimate of the intensity of transmis-
sion, equivalent to the basic reproduction ratio of a disease. It de-
scribes the total number of potentially infectious bites that would
eventually arise from all the mosquitoes in a population biting a
single perfectly-infectious human on a single day. TheMacdonald
model shows that vectorial capacity is highly sensitive to inter-
ventions that target the adult mosquito population, as they cause
a reduction in both the ratio of mosquitoes to humans and the
probability of mosquito survival (Macdonald 1952). If effective,
space spraying interventions will therefore have a direct impact
on the intensity of transmission. Assuming that the number of
infections arising in humans is relative to the number of infectious
bites received, this will further lead to a reduction in the number
of clinical cases of malaria (Smith 2007).
Why it is important to do this review
ITNs and IRS successfully exploit the anthropophilic (human-
biting), endophilic (indoor resting), endophagic (indoor biting),
and nocturnal behaviours of Africa’s most-efficient malaria vec-
tors, Anopheles gambiae and Anopheles funestus (Pates 2005; Sinka
2010). In areas of low to moderate transmission, these interven-
tions can be sufficient to reduce parasite prevalence to elimination
thresholds, but additional control measures will be required in set-
tings with high transmission or more challenging vector species
(Griffin 2010; Chaccour 2016). Space spraying may have a role
in reducing transmission in such settings as it will impact equally
upon behaviourally-different species. This is of particular interest
in the current and future climate as coverage of ITNs increases and
transmission via exophagic and zoophagic vector species becomes
more important.
TheWHO guidelines for judicious insecticide use state that space
spraying may be advisable as an emergency response to malaria
epidemics, providing resources are available for its immediate ap-
plication, and that the approach has previously had success against
the target species (Najera 2003). This is particularly recommended
for densely-populated areas with little potential for IRS, such as
camps for refugees and displaced people (WHO 2013; WHO
2015).
However, the use of space spraying for malaria control has been
limited. This may be due to the difficulty associated with under-
taking space spraying at night, when Anopheles mosquitoes are
most active, or the view that day-time fogs do not penetrate into
the resting sites of Anopheles mosquitoes (Najera 2003). Due to a
shortage of robust evidence, there remains widespread uncertainty
over whether space spraying has any impact on malaria transmis-
sion. Despite its use in a variety of epidemic and emergency situ-
ations, there is a perception that space spraying is only performed
as a public relations exercise (Najera 2003). Space spraying is also
expensive to implement on a routine basis as it requires both spe-
cialized equipment and trained staff, in addition to large quantities
of insecticide.
To achieve a target as ambitious as the eradication of malaria, com-
plete clarity is required regarding the effectiveness of available con-
trol methods. Understanding the impact of space spraying will al-
low the malaria community, including investors, researchers, and
disease control strategists, to make informed decisions regarding
the allocation of resources and to maximize the benefit of invest-
ments.
O B J E C T I V E S
Primary objective
To evaluate the impact of space spraying on malaria transmission
and vector populations, or the incremental impact when applied in
combination with other malaria control methods, in comparison
to equivalent conditions with no space spraying intervention.
Secondary objective
To guide future evaluations of strategies for which there is cur-
rently insufficient evidence to reliably assess the impact on malaria
transmission, by identifying the following.
• The range of space spraying strategies that have been
trialled.
• Potentially promising strategies that have been used and
warrant further evaluation.
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• Strategies that have been used and appear unlikely to
warrant further evaluation (for example, because they were found
to be infeasible or unacceptable).
M E T H O D S
Criteria for considering studies for this review
Types of studies
For our primary objective, we will include the following types of
studies.
• Cluster-randomized controlled trials (cRCTs) with:
◦ the unit of randomization being a cluster;
◦ evidence of baseline equivalence;
◦ monitoring of at least one transmission season; and
◦ at least two clusters per arm. As the two interventions
are distributed at a community level, we do not expect to find
trials with individual randomization.
• Interrupted time series (ITS) designs with:
◦ a clearly defined point in time when the intervention
occurred; and
◦ at least three data points before and three after the
intervention.
• Randomized cross-over studies with:
◦ a clearly defined point in time when the cross-over
occurred; and
◦ monitoring of at least two transmission seasons before
and after the cross-over.
• Controlled before-and-after studies (CBAs) with:
◦ a contemporaneous control group;
◦ monitoring of at least one transmission season before
and after the intervention; and
◦ at least two sites per treatment arm.
As part of our secondary objective to review a broader range of
space spraying strategies that have been trialled, wewill include the
following study designs that provide little or no reliable evidence
regarding effects.
• CBA studies with only one site per treatment arm.
• ITS studies with monitoring of at least two transmission
seasons before and after the intervention.
Types of participants
Children and adults living in malaria transmission settings.
Types of interventions
Intervention
• Interventions that utilise space spraying of insecticides with
the purpose of knocking down and killing adult Anopheles
mosquitoes.
• Interventions may include thermal fogging or cold aerosols
distributed through pedestrian (handheld/backpack), ground
vehicle, or aerial means.
• Insecticides applied in repetitions, with a minimum of two
sprays.
Control
• Equivalent regions that did not receive the above-named
space spraying interventions.
• Equivalent regions that received space-spraying with an
alternative public health insecticide.
• The control group must not have received any other
malaria-co-intervention(s) that differed from the intervention
arm.
Types of outcome measures
We will include studies that report any of the following outcomes.
Primary outcomes
• Incidence: measured as a count per person unit time of (a)
infections or (b) new infections, following radical cure to avoid
measuring pre-existing infections. We define infection as any
symptom, including fever, with confirmed parasitaemia (by
blood smear microscopy or rapid diagnostic test (RDT)).
• Parasite prevalence: the proportion of surveyed individuals
with confirmed parasitaemia.
Secondary outcomes
Epidemiological outcomes
• All-cause mortality.
• Number of people with severe disease: we will use site
specific definitions, provided they include (a) and either (b) or
(c): (a) demonstration of parasitaemia by blood smear; (b)
symptoms of cerebral malaria including coma, prostration, or
multiple seizures; (c) severe, life-threatening anaemia.
• Number of people with uncomplicated clinical malaria
episodes: we will use site-specific definitions, provided they
include (a) demonstration of malaria parasites by either blood
smear or RDT, or both, and (b) clinical symptoms including
fever detected passively or actively.
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Entomological outcomes
• Entomological Inoculation Rate (EIR): the estimated
number of bites by infectious mosquitoes per person per unit
time. This is measured using the human biting rate (the number
of mosquitoes biting an individual over a stated period measured
directly using human baits or indirectly using light traps, knock-
down catches, baited huts, or other methods of biting rate
determination) multiplied by the sporozoite rate.
• Adult mosquito density: measured by a technique
previously shown to be appropriate for the vector (measured
using human baits, light traps, knock-down catches, baited huts,
or other methods).
• Sporozoite rate.
Adverse events
Any indicators of adverse events of the intervention, including the
following.
• Reports of poisoning in humans due to increased exposure
to insecticide.
• Environmental impacts, such as changes to the biodiversity
and ecosystem, due to the addition of insecticides.
Search methods for identification of studies
Wewill attempt to identify all relevant trials regardless of language
or publication status (published, unpublished, in press, and in
progress).
Electronic searches
We will search the following databases using the search terms
and strategy described in Appendix 1, which we will adapt to
each of the specific databases: the Cochrane Infectious Diseases
Group Specialized Register; the Central Register of Controlled
Trials (CENTRAL), published in the Cochrane Library; MED-
LINE (PubMed); Embase (OVID); CAB Abstracts (Web of Sci-
ence); and LILACS. We will also search the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform (
http://www.who.int/ictrp/search/en/), ClinicalTrials.gov (https:/
/clinicaltrials.gov/), and the ISRCTN registry (www.isrctn.com/)
to identify ongoing trials, using ‘mosquito*’, “space spraying”,
“aerosol”, and “fogging” as search terms.
Searching other resources
Organizations (and pharmaceutical companies)
We will contact organizations, including the WHO and the Cen-
ters for Disease Control and Prevention (CDC), for ongoing and
unpublished trials.
Reference lists
We will also check the reference lists of all included studies for
further relevant studies.
Data collection and analysis
Selection of studies
Two review authors (JP and LC) will independently screen the
titles and abstracts of articles identified by the literature searches
for inclusion. They will assess the full-text articles of potentially
relevant trials for inclusion using an eligibility form that is based
on inclusion criteria. We will compare included trials and resolve
any disagreements by discussion and consensus, with arbitration
by a third review author (DM) if necessary. We will ensure that
multiple publications of the same trial are included only once. We
will list excluded studies, together with their reasons for exclusion,
in the ‘Characteristics of excluded studies’ table. We will illustrate
the study selection process in a PRISMA diagram.
Data extraction and management
Two review authors (JP and LC) will independently extract infor-
mation from the included studies using prepiloted, electronic data
extraction forms. In case of differences in extracted data, the two
review authors will discuss these differences to reach consensus. If
unresolved, further discussion will involve the third review author
(DM). In case of missing data, we will contact the original study
author(s) for clarification.
We will extract data on the following.
• Trial design: type of trial; method of participant selection;
adjustment for clustering (for cRCTs); sample size; method of
blinding of participants and personnel.
• Participants: trial settings and population characteristics;
recruitment rates; withdrawal and loss to follow-up.
• Intervention: description of intervention (active ingredient,
dose, formulation, droplet diameter, droplet density, ground or
aerial spraying method, ULV or cold fogging, frequency and
timing of application, size of treated area, buffer zone between
clusters, caged-mosquito outcomes); co-interventions;
description of control; duration of follow-up; coverage of
intervention and access to co-interventions; compliance of
intervention and any co-interventions.
• Outcomes: definition of outcome; diagnostic method or
surveillance method; passive or active case detection; number of
events; number of participants or unit time; statistical power;
unit of analysis; incomplete outcomes/missing data.
• Other:
◦ primary and secondary vector(s) species; vector(s)
behaviour (nature, stability, adult habitat, peak biting times,
exophilic/endophilic, exophagic/endophagic, anthropophilic/
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zoophilic); method of mosquito collection(s); phenotypic
insecticide resistance (based on WHO definitions if
supplementary WHO cylinder assays or CDC bottle bioassays,
or both, were performed whilst the trial was running); genotypic
insecticide resistance profile (either performed during the trial or
if the trial references data from previous studies done on the
same local vector population within the previous five years).
◦ malaria endemicity; eco-epidemiological setting;
population proximity and density; Plasmodium species.
For dichotomous outcomes, we will extract the number of par-
ticipants who experience each outcome and the number of par-
ticipants in each treatment group. For count data outcomes, we
will extract the number of outcomes in the treatment and control
groups, and the total person time at risk in each group or the rate
ratio, and a measure of variance (for example, standard error). For
numerical outcomes we will extract the mean and a measure of
variance (standard deviation).
For cRCTs we will record the number of clusters randomized;
number of clusters analysed; measure of effect (such as risk ratio,
odds ratio, or mean difference) with confidence intervals (CI) or
standard deviations; number of participants; and the intracluster
correlation coefficient (ICC) value. For non-randomized studies
(NRS), we will extract adjusted measures of intervention effects
that attempt to control for confounding.
Assessment of risk of bias in included studies
Two review authors (JP and LC) will independently assess risk of
bias for each included cRCT using the Cochrane ‘Risk of bias’
tool, and the five additional criteria listed in Section 16.3.2 of the
Cochrane Handbook for Systematic Reviews of Interventions relating
specifically to cluster-randomized trials (Higgins 2011). We will
assess the included NRS for risk of bias using the Cochrane Effec-
tive Practice and Organization of Practice (EPOC) ‘Risk of bias’
tool (Cochrane EPOC 2016). We will resolve any discrepancies
through discussion or, if necessary, we will consult the third review
author (DM). We will classify judgements of risk of bias as either
at low, high, or unclear risk of bias, using summary graphs (‘Risk
of bias’ summary and ‘Risk of bias’ graph) to display results.
Measures of treatment effect
Wewill compare intervention and control data using risk ratios and
rate ratios. We will use adjusted measures of effect to summarize
treatment effect from all included NRS.We will present all results
with their associated 95% CIs.
Unit of analysis issues
If included cRCTs have not adjusted for clustering in the analysis,
wewill attempt to adjust data before combining it.Wewill attempt
to adjust the data by multiplying standard errors by the square
root of the design effect (Higgins 2011). If the trial does not report
the ICC value, then we will estimate the ICC from a similar trial
if possible, or by searching external sources for example ICCs.
Alternatively, we will not include cRCTs that have not adjusted for
clustering in the meta-analysis but will present results in a separate
table.
Dealing with missing data
In case of missing data, we will apply available-case analysis, only
including data on the known results. The denominator will be
the total number of participants who had data recorded for the
specific outcome. For outcomes with no missing data, we plan to
perform analyses on an intention-to-treat basis. We will include
all participants randomized to each group in the analyses and will
analyse participants in the group to which they were randomized
to.
Assessment of heterogeneity
We will inspect forest plots for overlapping CIs and will assess
statistical heterogeneity in each meta-analysis using the I² statistic
and Chi² test values. We will regard heterogeneity as moderate if
I² statistic values are between 30% to 60%; substantial if they are
between 50% to 90%; and considerable if they are between 75%
to 100%. We will regard a Chi² test statistic with a P value > 0.10
indicative of statistically significant heterogeneity. We will explore
clinical and methodological heterogeneity through consideration
of the trial populations, methods and interventions, and by visu-
alization of trial results.
Assessment of reporting biases
If there are 10 or more included trials in each meta-analysis, we
will investigate reporting biases (such as publication bias) using
funnel plots. We will assess funnel plot asymmetry visually, and
use formal tests for funnel plot asymmetry (Harbord 2006). If we
detect asymmetry in any of these tests or by a visual assessment,
we will explore reasons for asymmetry.
Data synthesis
We will analyse data using Review Manager 5 (RevMan 5)
(RevMan 2014).Wemay pool data fromRCTs in a meta-analysis.
If we judge that included NRS are both reasonably resistant to
biases and relatively homogeneous, we may combine data across
studies using meta-analysis (Taggart 2001). We will not include
NRS in meta-analyses with RCTs. Meta-analyses for cRCTs will
use the crude or unadjusted effect estimates, while meta-analyses
for NRS will use the adjusted measures of effect, as per Section
13.6.1 of the Cochrane Handbook for Systematic Reviews of Inter-
ventions (Reeves 2011).
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We will use fixed-effect meta-analysis to combine data if hetero-
geneity is absent. If considerable heterogeneity is present, we will
combine data using random-effects meta-analysis and report an
average treatment effect. We will decide whether to use fixed- or
random-effects based on the consideration of clinical andmethod-
ological heterogeneity between trials, as described previously.
We will assess the certainty of the evidence using the GRADE
approach (Guyatt 2011).We will rate the certainty of the evidence
for each primary and adverse event outcome, as described by
Balshem 2011.
• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate. The true effect is likely to be close to the estimate of
the effect.
• Low: our confidence in the effect estimate is limited. The
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate. The true effect is likely to be substantially different
from the estimate of effect.
RCTs start as high certainty evidence but can be downgraded if
there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias. Studies can also be upgraded if there is a large effect; a dose
response effect; and if all plausible residual confounding would
reduce a demonstrated effect or would suggest a spurious effect if
no effect was observed (Balshem 2011). We will summarize our
findings in a ’Summary of findings’ table.
Subgroup analysis and investigation of heterogeneity
We plan to perform the following subgroup analyses.
• Seasonality of malaria (perennial transmission/seasonal
transmission/outbreak or high-risk settings).
• Spray equipment used: ground sprays, that is using hand-
held or vehicle-mounted equipment, or aerial sprays).
• Time of spraying (between 7am and 6.59pm or 7pm and
6.59am).
We will assess differences between subgroups using the Chi² test,
with a P value of less than 0.05 indicating statistically significant
differences between subgroups.
Sensitivity analysis
Wewill perform sensitivity analysis on the primary outcome to see
the effect of exclusion of trials at high risk of bias (for allocation
concealment and incomplete outcome data) on overall results. If
the ICC value is estimated, we will undertake sensitivity analyses
to investigate the impact of varying the ICC on results from the
meta-analysis.
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A D D I T I O N A L T A B L E S
Table 1. WHO-recommended insecticides for space spraying against mosquitoes
Compound and formulation Concentration (g Al/ha)
Cold fog Thermal fog
Deltamethrin ULV 0.5 to 1.0 0.5 to 1.0
Deltamethrin EW 1.0 -
Lambda-cyhalothrin EC 1.0 to 2.0 2.0
Malathion EW and ULV 112 to 600 112 to 600
d-d, trans-cyphenothrin EC 3.5 to 4.0 3.5 to 4.0
Abbreviations: EC: emulsifiable concentrate; EW: emulsion, oil in water; ULV: ultra-low volume liquid; AI: active ingredient
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A P P E N D I C E S
Appendix 1. MEDLINE search strategy
Search set Search terms
1 Malaria* Title/Abstract , [Mesh]
2 “Insect Vectors”[Mesh] OR vector* ti, ab OR mosquito* or anophel* Title/Abstract
3 1 or 2
4 “Mosquito Control”[Mesh]
5 “Anopheles”[Mesh]
6 3 or 4 or 5
7 ((((aerosol*) OR droplet*) OR “cold fog*”) OR “thermal fog* ”) OR space spray* OR fogging ORmisters Title/Abstract
8 “Mist Blower”OR“fumigant canister*”OR“aerial spray*”OR“spray* equipment”OR “ultralow volume”OR“ultralow-
volume” OR ULV Title/Abstract
9 “Aerosols”[Mesh]
10 “Fumigation”[Mesh]
11 7 OR 8 OR 9 OR 10
12 6 AND 11
This is the preliminary search strategy for MEDLINE (PubMed). We will be adapt it for other electronic databases. We will report all
search strategies in full in the final version of the review.
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